C olon cleansing in preparation for colonoscopy continues to be a significant challenge for physicians and patients. The demand for colonoscopy continues to increase in North America and worldwide, largely in response to national colon screening programs. This demand has placed significant stress on existing colonoscopy resources. Effective colon cleansing becomes increasingly important in this environment because poor cleansing impacts the duration of the procedure and the interval recommended between procedures. The ability of the patient to tolerate the preparation is also important, because it can affect the quality of the preparation and has been identified as the most important factor underlying patient compliance in colonoscopy surveillance programs (1) . Oral sodium phosphate (NaP) solution emerged in the 1990s as a popular colon cleansing agent because of favourable efficacy and patient tolerability (2) (3) (4) . However, safety issues have emerged which have led to questions concerning the risk/benefit of this agent (5, 6 ). The present article provides an overview of the qualities of an optimum colon cleansing preparation, the relative advantages and disadvantages of oral NaP solution, and the emerging trends and alternatives in colon cleansing. The present review provides a context for which the question of 'whether the use of oral NaP solution still makes sense', for bowel preparation in Canada, can be examined.
Quality of the optimum Colon Cleansing Regimen
There are three fundamental components to the optimum colon cleansing preparation: cleansing efficacy, patient tolerability and safety. Cleansing efficacy affects the polyp detection rate (7, 8) and duration of the procedure (9) , and can influence the duration between colonoscopies in screening programs. Cleansing in the right colon is particularly important because this region presents the greatest challenge (10, 11) . Furthermore, there is increased recognition that flat polyps have significant premalignant potential and are preferentially found in the right colon (12, 13) . Patient tolerability of the preparation is also very important because it can lead to morbidity and, rarely, mortality (eg, vomiting resulting in Boerhaave's syndrome); indirectly affects the quality of the cleansing (eg, patient cannot ingest the full preparation); and is recognized to be an important determinant of compliance in colon screening programs (1). The issue of safety is magnified by the increasing number of healthy patients undergoing an elective procedure to prevent disease and by an aging population being subjected to colonoscopy. Ultimately, these factors must also be balanced against the implications of missing a clinically significant lesion (eg, flat polyp with high-grade dysplasia or carcinoma) due to poor cleansing or noncompliance due to concerns about the cleansing regimen which may result in a serious adverse outcome (eg, interval colon cancer in a screening program). provides superior colon cleansing, particularly when given in a night/morning split dosage (see split-dose regimens below), and is much better tolerated than 4 L PEG solutions. However, split-doses of PEG were typically not used in these studies. It has been well recognized that oral NaP solution has potential safety issues because it is a small-volume osmotic agent with the ability to draw fluid from the intravascular space and cause transient hyperphosphatemia (4) . However, extensive clinical trials failed to demonstrate any clinically significant sequelae resulting from these actions (4) . A review in the early 2000s (4) documented that more than 2500 patients had been studied in clinical trials and there were no reports of serious adverse events. There have been a small number of case reports documenting serious adverse events; however, these appeared to be the result of inappropriate dosing and/or patient selection (eg, patients with contraindications such as renal failure or bowel obstruction). Data from the United States Food and Drug Administration (FDA) and Health Canada in early 2000 suggested the serious adverse event rate, including mortality, was similar for NaP and PEG (4). However, in 2003, a case report (16) suggested an association between chronic renal failure and nephrocalcinosis with the use of oral NaP for colon cleansing. This was followed the next year by a case series of 23 patients (5) detected from a large database of renal biopsies. The risk factors are not entirely clear, but female sex, cocomitant use of medications such as diuretics, angiotensinconverting enzyme inhibitors/angiotensin receptor blockers, underlying subclinical renal disease and the hydration status of the patient have been suggested as possible associations (5, 6, 17) . Recent retrospective and prospective studies specifically examining the impact of NaP on renal function have not clearly identified a systematic decline in renal function (Table 2) . However, of the five retrospective studies (18) (19) (20) (21) (22) , the largest (22) reported an OR of 2.35 (doubling of serum creatinine; number needed to harm = 298). Three prospective studies (18, 23, 24) , two of which are reported in abstract form only (23, 24) , have not revealed an association between the use of oral NaP and the subsequent development of renal failure. Despite these findings, small numbers of case reports suggesting an association between the use of oral NaP and renal failure continue to emerge (25, 26) . Most experts believe that there is an association but that the risk is low.
The United States FDA issued a safety alert in December 2008, stating that oral NaP for colon cleansing before colonoscopy should only be available by prescription. As a result, the CB Fleet Company (Lynchburg, USA) immediately issued a voluntary recall of their over-the-counter products for colon cleansing in the United States. The FDA's issuance followed a review after "it received more than 20 reports of a rare, but serious from of kidney failure among patients taking the drugs, known as oral phosphate products". More details can be found on the FDA Web site (www.fda.gov/medwatch/safety/2008/ safety08.htm#OSP). NaP tablets remain available in the United States, but the FDA recommended that their use be restricted to appropriate candidates who are 55 years of age and younger.
To date, oral NaP solution remains available as an over-the-counter product for colonoscopy in Canada.
CuRRent tRenDs toWaRD optimizing the use of oRal nap anD alteRnatiVe Cleansing Regimens
In the past decade, lower dose solutions, split dosing, and a mixture of sodium picosulfate, magnesium oxide and citric acid (Pico-Salax [Ferring Inc, Canada] -presently not available in United States) -have been introduced as newer strategies. There is growing interest, particularly in the United States, in the use of lower-dose preparations of PEG, oral NaP and NaP tablets (Table 3) . Low-dose PEG solution (2 L) combined with bisacodyl tablets (Halflytely [Braintree Laboratories Inc, USA] -not available in Canada) have been shown to improve 
PEG, n=154
Change in serum creatinine from baseline NaP resulted in minor increase in serum creatinine (8.8 µmol/L) not believed by authors to be clinically significant (only reached significance when compared with PEG, which decreased serum creatinine)
Russman et al (20) Retrospective cohort PEG, n=269
NaP, n=2083
Glomerular filtration rate <60 mL/min and decrease from baseline of >10 mL/min
No association with use of NaP patient tolerance over the standard 4 L dose, and studies (27, 28) did not detect differences in efficacy. However, the studies were not designed as equivalence trials and one study showed a significant increase in inadequate preparations in the low-dose group (27) . Therefore, it remains possible that these lower volume preparations are not as efficacious. There are limited data comparing this lower volume of PEG with oral NaP (29, 30) but the available data suggests less efficacy than with oral NaP (Table 3) . Similarly, lower doses of oral NaP (45/30 mL -not available in Canada) are now marketed which should reduce the osmotic effect and phosphate load. Studies (31) have not detected a difference in efficacy between the low dose and standard dose but there were numerically more preparations with poorer cleansing in the lower-dose group, especially in men.
Thus, there is some concern that the reduced oral NaP dose may compromise efficacy in some patients. Recent studies (32, 33) examining a decreased number of NaP tablets did not detect differences in efficacy compared with standard tablet doses. Split dosing has emerged as an important factor in cleansing efficacy and may also impact patient tolerability in large volume preparations (Table 4) . This factor has become increasingly important as colonoscopy units expand their examination times from the morning to the full day. There is growing supportive data for all bowel preparations that the quality of the preparation declines considerably when the interval from the last dose exceeds 12 h, and possibly between 6 h to 12 h (10). Studies ( Table 4 ) have shown that split dosing with NaP and PEG enhances efficacy (10,34,35 ). Pico-Salax was recently introduced in Canada and has been used in the United Kingdom since 1981. In Canada, it has become increasingly popular among patients and physicians. A recent review (36) suggests this agent is better tolerated than standard regimens of NaP and PEG and has a very good safety profile (based on small studies with safety data and the paucity of serious adverse event reporting). However, the efficacy of this agent remains to be established because it is unclear whether the efficacy is similar to NaP and PEG (36) .
ConClusions
The role of oral NaP solution as a colonic cleansing agent is evolving and its future is unclear. In response to recent the FDA directives, oral NaP solution is no longer available as a colon cleansing agent in the United States but it remains available in Canada as an over-the-counter product. Given the safety concerns with this agent, the recent regulatory developments in the United States, and the recent availability of alternative products in Canada, United Kingdom, Europe and Australia that better meet the criteria of an 'optimum bowel preparation' (eg, Pico-Salax with or without adjunct[s]) it is difficult to advise the continued use of oral NaP solution unless physicians and/or patients have a specific need that cannot be met by alternative products (eg, patient unable to tolerate other agents). If so, physicians and patients must be aware of its potential safety concerns and take appropriate measures to ensure that these risks are minimized. Contraindications to its use need to be strictly adhered to (Table 5 ) and the importance of adequate hydration stressed; oral NaP solution should be avoided in the extremes of age. NaP tablets are not available in Canada, and in the Unites States, the FDA has recommended that the use of prescription NaP tablets be restricted to low-risk patients (ie, younger than 55 years of age). Prescription use of tablets should follow practices outlined for NaP solution (Table 5) .
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